The case for & against
Bull & Bear analysis
Bearish
Cross Country Healthcare, Inc. (NASDAQ: CCRN) is a leading provider of staffing and workforce solutions in the healthcare sector, primarily focused on staffing services across various areas such as travel nursing, allied health, physician staffing, and education. As a prominent player in the healthcare staffing industry, Cross Country is navigating ongoing transitions as healthcare systems aim to optimize labor costs while maintaining service quality, all in the context of an upcoming merger that may reshape its operational dynamics.
Bull says
- ↑Orders +20% since Q2 start indicates stabilizing demand across specialties
- ↑Q4 2025 cash $109M, zero debt provides M&A and buyback flexibility
- ↑Home-based staffing revenue up 13% drives higher-margin diversification
- ↑$20M+ invested in IntelliFi platform to boost labor efficiency
- ↑800K shares repurchased in Q2 2024 shows management confidence
- ↑Strong liquidity and low leverage support strategic investments
Bear says
- ↓Travel nurse & allied revenue down 48% YoY strains top-line growth
- ↓Gross margins fell 200 bps YoY as pay rates outpace bill rates
- ↓Q2 2024 revenue guided at $330–340M, down 10–13% sequentially
- ↓Hyper-competitive staffing environment pressures compensation and share
- ↓Ongoing regulatory changes add compliance risk and operational distractions
- ↓Weak profitability and growth factor scores suggest valuation risk
Investment themes with CCRN
Health Care Providers↓ -0.61%
UNH · CVS · HCA
Earnings Call · Q4 2023 · Mgmt. Guidance
Updated 06-22-2026neutral
Transcript signals
Bull points
- We reported adjusted EBITDA of $21 million, representing an adjusted EBITDA margin of 5%. Though revenue was above the high end of our expectations, our adjusted EBITDA was impacted by an increase in our bad debt expense, One of our MSP clients has fallen behind on payments for services rendered throughout the pandemic, leading to deterioration in the aging that requires to take an additional reserve of $2 million for that specific account.
- Excluding the bad debt charge, we would have reported approximately $23 million in adjusted EBITDA, representing a 6% adjusted EBITDA margin for the quarter.
- we remain well positioned to make further investments in technology and accretive acquisitions, as well as to continue repurchasing shares under our $100 million share repurchase plan.
Bear points
- Consolidated revenue for the fourth quarter of $414 million was down 6% sequentially and 34% over the prior year, driven by the continued normalization in both travel demand and bill rates.
- The majority of the decrease relates to lower salary and benefit costs associated with our reductions in headcount, as well as lower variable compensation following the historic performance throughout the pandemic.
- As bill pay spreads remain compressed amidst softer demand, we continue to emphasize the importance of continuous productivity and efficiency gains.
Read full transcript analysis ›